Newsroom

Sight Sciences Names Jesse Selnick Chief Financial Officer

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye treatment, today announced the appointment of Jesse Selnick...

read more +
Sight Sciences Expands Surgical Portfolio with FDA Clearance of the OMNI™ Surgical System

Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic device company, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for its OMNI™ Surgical System, a surgical tool dually indicated...

read more +
Sight Sciences Secures $10MM in Oversubscribed Series C Financing

Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company today announced it has closed an oversubscribed $10 million Series C round of growth financing and strengthened its leadership team with...

read more +
Sight Sciences Announces Expanding Management Team of Seasoned Medical Device Experts

Sight Sciences, Inc., a venture-backed, commercial stage ophthalmic medical device company announced an expansion of its management team to support its recent regulatory milestones and commercial success. New hires include...

read more +
Sight Sciences Receives Full Investigational Device Exemption (IDE) Approval from the US FDA to Initiate the VISCO™360 Versus SLT Glaucoma Trial

Sight Sciences, Inc., a venture-backed, commercial-stage ophthalmic medical device company announced today that it has received full IDE approval from the FDA to initiate the world’s first clinical trial comparing...

read more +
Sight Sciences Announces the Closing of its $7MM Series B Financing Led by Hicks Equity Partners

Sight Sciences, Inc., a venture-backed, commercial-stage ophthalmic medical device company today announced it has closed a $7 million Series B round of financing. The round was led by Hicks Equity...

read more +